445 completed. 445 Phase 3, 33 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 445 | Completed 445 |
| Phase 2 | 33 | Completed 33 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) Alectinib, Cisplatin, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Completed | Hoffmann-La Roche | 11 | 2024-11-18 | 2026-08-19 |
| ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer HS-20093, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Hansoh BioMedical R&D Company | 461 | 2024-07-04 | 2026-10-16 |
| A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) GME751, Keytruda-EU - Metastatic NSCLC | Phase 3 | Completed | Sandoz | 218 | 2024-04-29 | 2026-04-09 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC Pembrolizumab, Sintilimab - Non-small Cell Lung Cancer | Phase 3 | Completed | Hunan Province Tumor Hospital | 210 | 2022-09-23 | 2026-06-03 |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) Irinotecan, Lurbinectedin, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Completed | PharmaMar | 705 | 2022-07-22 | 2026-10-21 |
| Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) pembrolizumab/vibostolimab, durvalumab, cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | Merck Sharp & Dohme LLC | 610 | 2022-05-03 | 2026-08-28 |
| Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis 100% Aloe Vera Juice, Magic Mouthwash, Salt and Baking soda rinse - Oral Cavity Cancer, Head and Neck Cancers - Tonsils | Phase 3 | Completed | Covenant Health Cancer Center | 100 | 2022-01-20 | 2024-10-10 |
| Bintrafusp Alfa Program Rollover Study Bintrafusp alfa - Lung Cancer, Cancer | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 22 | 2021-12-01 | 2026-02-02 |
| Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin - Non-small Cell Lung Cancer | Phase 3 | Completed | Hutchison Medipharma Limited | 216 | 2021-11-22 | 2026-05-27 |
| Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Durvalumab, Cisplatin, Carboplatin - Extensive-stage Small Cell Lung Cancer | Phase 3 | Completed | AstraZeneca | 152 | 2021-11-11 | 2025-05-23 |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) Pembrolizumab SC, Pembrolizumab IV, Paclitaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 531 | 2021-08-05 | 2026-10-07 |
| A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC ZKAB001, Placebo, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 3 | Completed | Lee's Pharmaceutical Limited | 498 | 2021-07-15 | 2024-02-02 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC Camrelizumab, Placebo, Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 60 | 2021-05-28 | 2026-05-20 |
| Educating QUitline Callers About Lung Cancer Screening Should I Screen website, Should I Screen print booklet - Population at Risk | Phase 3 | Completed | Georgetown University | 298 | 2021-05-27 | 2023-03-29 |
| Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients Trilaciclib, carboplatin, etoposide，or Topotecan, placebo, carboplatin, etoposide，or Topotecan - Extensive-stage Small-cell Lung Cancer | Phase 3 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 95 | 2021-05-25 | 2024-07-10 |
| Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT Sodium Fluoride F-18 Injection, Technetium[99mTc] Methylenediphosphonate Injection - Bone Metastases | Phase 3 | Completed | HTA Co., Ltd. | 280 | 2021-03-29 | 2022-11-14 |
| Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer Chiauranib, Placebo - Small Cell Lung Cancer | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 184 | 2021-03-05 | 2024-12-09 |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma | Phase 3 | Completed | PrECOG, LLC. | 214 | 2021-02-18 | 2026-10-22 |
| Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy - Advanced Lung Carcinoma, Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 33 | 2021-01-20 | 2026-07-21 |
Showing 20 of 445. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (315) · Lung Neoplasms (162) · Small Cell Lung Carcinoma (50) · Neoplasms (23) · Adenocarcinoma of Lung (22) · Neoplasm Metastasis (19) · Parkinson Disease 4, Autosomal Dominant Lewy Body (14) · Breast Neoplasms (12) · Mesothelioma, Malignant (11) · Brain Neoplasms (10) · Adenocarcinoma, Bronchiolo-Alveolar (8) · Cachexia (8) · Pleural Effusion, Malignant (8) · Prostatic Neoplasms (8) · Esophageal Neoplasms (7)
Neoplasms by Site (444) · Respiratory Tract Neoplasms (442) · Respiratory Tract Diseases (440) · Lung Diseases (433) · Neoplasms (422) · Bronchial Neoplasms (358) · Carcinoma, Bronchogenic (356) · Lung Neoplasms (274) · Neoplasms by Histologic Type (55) · Neoplasms, Glandular and Epithelial (48) · Pathological Conditions, Signs and Symptoms (48) · Carcinoma (31) · Pathologic Processes (31) · Adenocarcinoma (23)
Carboplatin (111) · Cisplatin (88) · Paclitaxel (69) · Pemetrexed (66) · Docetaxel (58) · Gemcitabine (39) · Etoposide (31) · Erlotinib Hydrochloride (28) · Radiotherapy (27) · Bevacizumab (25) · pembrolizumab (23) · Gefitinib (21) · Vinorelbine (21) · atezolizumab (16) · Nivolumab (14)
Hoffmann-La Roche (28) · Eli Lilly and Company (21) · Merck Sharp & Dohme LLC (20) · Alliance for Clinical Trials in Oncology (17) · Bristol-Myers Squibb (15) · AstraZeneca (14) · Boehringer Ingelheim (12) · National Cancer Institute (NCI) (9) · Pfizer (9) · European Organisation for Research and Treatment of Cancer - EORTC (7) · GlaxoSmithKline (7) · Intergroupe Francophone de Cancerologie Thoracique (7) · NCIC Clinical Trials Group (7) · Radiation Therapy Oncology Group (6) · Sanofi (6)
United States (205) · China (135) · Italy (126) · Spain (124) · France (122) · Canada (120) · Germany (119) · South Korea (107) · Poland (105) · United Kingdom (105) · Australia (92) · Hungary (91) · Russia (90) · Taiwan (89) · Belgium (85)
Randolph S. Marks, MD (4) · Giuseppe Giaccone, MD, PhD (3) · Nathan Levitan, MD (3)
PMID 25881079, PMID 37465924, PMID 38642841, PMID 28472437, PMID 36184621, PMID 37419867, PMID 39113428, PMID 15764775, PMID 22266043, PMID 23948351, PMID 25589191, PMID 26051236, PMID 26768165, PMID 26823294, PMID 26906526, PMID 27130468, PMID 27138015, PMID 27601237, PMID 28501139, PMID 29653820, PMID 31395089, PMID 32305010, PMID 33075149, PMID 33231285, PMID 33300372, PMID 33337539, PMID 33358660, PMID 34409776, PMID 35073727, PMID 35511917, PMID 35930972, PMID 36793385, PMID 36795388, PMID 37922432, PMID 38159809, PMID 38383458, PMID 39369790, PMID 39661917, PMID 39992021, PMID 40498298, PMID 41666849, PMID 42579028, PMID 11181777, PMID 11917283, PMID 12377323, PMID 12431965, PMID 14581415, PMID 14731343, PMID 14736927, PMID 14973997
2014 (12), 2015 (12), 2017 (8), U10CA031946 (8), 2009 (7), 2018 (7), 2016 (6), 2019 (6), 2023 (4), 2008 (3), U10CA032102 (3), 2005 (2), U10CA021115 (2), 2004 (1), N1CN25476A-85-0-1 (1)